Form 4: MeiraGTx Holdings Chief Medical Officer Reports Share Transactions

Chief Medical Officer of MeiraGTx Holdings, Robert K. Zeldin, reports the vesting of restricted share units and subsequent tax withholding.

Summary

• Robert K. Zeldin, Chief Medical Officer of MeiraGTx Holdings, reported transactions involving the company's ordinary shares.
• On January 7, 2025, 17,500 restricted share units vested, converting into 17,500 ordinary shares.
• Additionally, 6,886 shares were withheld to cover tax obligations related to the vesting at a price of $6.34 per share.
• Following these transactions, Zeldin directly owns 105,072 ordinary shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative, but is a normal part of company operations.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the vesting of previously granted equity awards.

Comparison to Industry Standards

• The vesting of restricted share units is a standard practice in executive compensation across the biotechnology industry.
• Tax withholding on vesting is also a common procedure to cover the tax liabilities of the executive.

Stakeholder Impact

• The transaction has a minor impact on the total number of shares outstanding.
• The vesting of shares is part of the executive's compensation package and is not expected to have a significant impact on shareholders.

Key Dates

Keywords

MeiraGTx Holdings, MGTX, Robert K. Zeldin, Chief Medical Officer, share vesting, restricted share units, insider trading, SEC Form 4